Brief: Arch Biopartners Expands Dosing In Phase I Trial For Metablok To Increase Dose Range For Future Phase II Studies
04/03/2020 15:08
March 4 (Reuters) - Arch Biopartners Inc ARCH.V :
* ARCH BIOPARTNERS EXPANDS DOSING IN PHASE I TRIAL FOR
METABLOK TO
INCREASE DOSE RANGE FOR FUTURE PHASE II STUDIES
* ARCH BIOPARTNERS- DOSING OF EIGHT ADDITIONAL VOLUNTEERS
HAS
BEGUN AND DOSING IS EXPECTED TO END DURING MARCH 2020
Source text for Eikon: ID:nGNX7H9f5p
Further company coverage: ARCH.V
(((Reuters.Briefs@thomsonreuters.com);;))
Recent news on Arch Biopartners
See all newsBrief: Arch Biopartners To Expand Phase Ii Cardiac Surgery-Associated Acute Kidney Injury Trial To The US
Brief: Arch Biopartners Closes Non-Brokered Private Placement
Brief: Arch Strengthens Its Position As A Leading Kidney Therapeutics Company With The Acquisition Of A Breakthrough Platform To Develop New Drugs Targeting Chronic Kidney Disease (Ckd)
Brief: Arch Biopartners Closes Non-Brokered Private Placement
Brief: Arch Biopartners Announces Ontario Research Ethics Board Approval To Start Phase II Trial For LSALT Peptide